Skip to content

Cohu COHU Term loan

Term loan at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$0-100%
Block logo
BlockXYZ
$283.56M
Corpay logo
CorpayCPAY
$2.14B+45.9%
Coty logo
CotyCOTY
$2.1M-77.7%
GeneDx Holdings logo
GeneDx HoldingsWGS
$5.13M+64.2%
Phinia logo
PhiniaPHIN
$24M-4.0%

Other financials

Income statement

See full
Revenue$125.1M+29.3%
Gross profit$57.9M+36.8%
Operating income-$11.2M+59.2%
Net income-$12.1M+60.8%
EPS (diluted)-$0.26+60.6%

Balance sheet

See full
Cash & equivalents$210.9M+38.9%
Total debt$328.9M+974%
Total equity$769.0M-7.1%
Total assets$1.2B+26.6%

Cash flow

See full
Operating cash flow$10.3M+201%
CapEx$2.0M-81.5%
Free cash flow$8.3M+139%

Valuation

See full
Market cap$3.04B+109%

Profitability

See full
Gross margin43.5%-0.9pp
Operating margin-11.1%-3.5pp
Net margin-11.5%-3.7pp
FCF margin8.3%

Returns & leverage

See full
Return on equity-7%-1.6pp
Debt / equity0.4×+0.4×
Current ratio6.4×+1.2×

Where this comes from

Reported directly by Cohu in its filing.

Tagged under the XBRL concept us-gaap:LoansPayableToBankCurrent.

The official record: Cohu’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cohu's term loan.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cohu's term loan?
Cohu (COHU) reported term loan of $1.22M in Q1 2026.
How has Cohu's term loan changed year-over-year?
Cohu's term loan increased by 4.6% year-over-year, from $1.16M to $1.22M.
What is the long-term trend for Cohu's term loan?
Over 5 years (2020 to 2025), Cohu's term loan has grown at a -16.6% compound annual growth rate (CAGR), from $3.08M to $1.24M.
What does term loan mean?
This represents the portion of bank debt and short-term credit facilities that is due for repayment within one year. It serves as a key indicator of a company's immediate liquidity requirements and its reliance on short-term financing to fund operations. Monitoring this balance helps investors assess the company's ability to meet near-term debt obligations without refinancing.